Drug Discovery

#Biomarkers #Drug discovery #Parkinson's #Protein chemistry / Proteomics #Webinar

Webinar: Large-scale proteomics enables early detection and disease interception

What if you could see diseases like Parkinson’s coming years before symptoms appear? In this webinar, hosted by DDW and supported by Standard BioTools, Benoit Lehallier, PhD, Senior Director, Data Science at Alkahest will share how SomaScan Technology, alongside complementary proteomic platforms, uncovers signals that predict disease risk… Read More

Webinar date:
Supported by Standard BioTools
#News

#Artificial intelligence (AI) #Drug discovery #Investment #Machine learning

Pharmacelera raises $6m to advance AI drug discovery  

Deep tech company Pharmacelera has raised $6 million in an investment round to help accelerate its expansion in the United States and grow its platform.   Pharmacelera uses its proprietary quantum mechanics and artificial intelligence (QaiM) algorithms to find novel and diverse molecular candidates across the chemical “exaSpace”.   The company says its algorithms can generate… Read More

#News

#Biomarkers #Drug discovery #Parkinson's #Protein chemistry / Proteomics #Webinar

Webinar: Is trajectory-based profiling the next frontier in precision medicine?

What if you could see diseases like Parkinson’s coming years before symptoms appear? In this webinar, hosted by DDW and supported by Standard BioTools, Benoit Lehallier, PhD, Senior Director, Data Science at Alkahest will share how SomaScan Technology, alongside complementary proteomic platforms, uncovers signals that predict disease risk… Read More

Webinar date:
Supported by Standard BioTools
#News

#AI #Drug discovery #Women's health

Partnership to develop treatments for gynaecological diseases 

Tejin Pharma has partnered with pharmaceutical company Aska Pharmaceutical to develop treatments for gynaecological diseases.  As per the agreement, the companies will collaborate to accelerate the early-stage drug discovery process aimed at identifying innovative therapeutic candidates.   The companies intend to develop novel small-molecule drug candidates, a process which… Read More

#News

#Drug discovery #John Hopkins University #Syngene

Syngene and John Hopkins University to advance drug discovery  

Syngene International has announced a strategic collaboration with John Hopkins University to advance early-stage drug discovery programmes.  The collaboration will incorporate Syngene’s SynVent, a fully integrated drug discovery and development platform that spans discovery biology, medicinal and synthetic chemistry, DMPK (Drug Metabolism and Pharmacokinetics), toxicology, and early development.  … Read More

#Business & Investment #News

Parkinson's disease
#Biomarkers #Drug discovery #Parkinson's #Protein chemistry / Proteomics #Webinar

Webinar: Parkinson’s biomarkers detected 12 years pre-symptomatically

What if you could see diseases like Parkinson’s coming years before symptoms appear? In this webinar, hosted by DDW and supported by Standard BioTools, Benoit Lehallier, PhD, Senior Director, Data Science at Alkahest will share how SomaScan Technology, alongside complementary proteomic platforms, uncovers signals that predict disease risk… Read More

Webinar date:
Supported by Standard BioTools
#News

#Drug development #Emulate #FDA #SLAS2026

Emulate showcases organ-chip platform at SLAS2026 

Emulate has brought its AVA Emulation System to SLAS2026, showcasing the potential to accelerate drug development with a first-of-its-kind high-throughput organ-chip platform.  The AVA Emulation System, launched in June 2025, is a self-contained instrument that cultures, incubates, and images up to 96 independent organ-chip samples in… Read More

#News

#Assays #Drug discovery #Oncology #Revvity #SLAS2026 #SPT Labtech

SLAS2026: Day One Round-Up  

DDW covers some of the biggest announcements from the first day of SLAS2026.     Carterra launches high-throughput SPR instrument   High-throughput technology provider Carterra  launched its Carterra Vega High-Throughput Surface Plasmon Resonance (HT-SPR) instrument – the industry’s first 48-channel SPR platform. The instrument has been designed to deliver 12-fold higher throughput versus the… Read More

#News

#Drug discovery #High throughput screening #Revvity #SLAS2026

Revvity launches high-impact discovery platform 

Revvity launched multiple new discovery platforms and technologies at SLAS2026, all designed to accelerate high-throughput drug discovery workflows.   The company debuted its Opera Phenix OptIQ high-content screening system, the EnVision Nexus One multimode plate reader, and the AssayMate workstation.   The Opera Phenix OptIQ high-content screening system is designed to reduce bottlenecks in phenotypic screening and… Read More

#News

Cannabinoid research
#Assays #BMG Labtech #Cannabinoid #Drug discovery

The study of cannabinoid-based drugs: developments and opportunities

This paid-for advertorial by BMG Labtech appeared in DDW Volume 27 – Issue 1, Winter 2025/2026.   Scientists are exploring new strategies to advance drug discovery and development related to cannabinoid research due to significant unmet needs in different therapeutic areas. Microplate-based interaction assays show promise for the study of a wide range of cannabinoid signalling events. Developments in cannabinoid research… Read More

#Exclusive Content

Researcher in a medical lab
#Biomarkers #Drug discovery #Parkinson's #Protein chemistry / Proteomics #Webinar

Webinar: Predict disease risk long before diagnosis

What if you could see diseases like Parkinson’s coming years before symptoms appear? In this webinar, hosted by DDW and supported by Standard BioTools, Benoit Lehallier, PhD, Senior Director, Data Science at Alkahest will share how SomaScan Technology, alongside complementary proteomic platforms, uncovers signals that predict disease risk… Read More

Webinar date:
Supported by Standard BioTools
#News